MRK registry changes
Status changes, moved primary completion and completion dates, and results first posted on ClinicalTrials.gov, for trials linked to listed companies. Newest detection first.
Newest change detected Nov 19, 2026, 8:47 AM ET
| Detected | Trial | Change | Now | Before | Record updated |
|---|---|---|---|---|---|
| Nov 19, 2026, 8:47 AM ET | Completion date | Nov 16, 2026 (actual) | Locked | Locked | |
| Nov 19, 2026, 8:47 AM ET | Completion date | Jun 30, 2030 (sponsor estimate) | Locked | Locked | |
| Nov 17, 2026, 9:52 AM ET | Completion date | Oct 27, 2026 (actual) | Locked | Locked | |
| Nov 17, 2026, 9:52 AM ET | Completion date | Aug 19, 2031 (sponsor estimate) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Dec 31, 2026 (sponsor estimate) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Dec 27, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Dec 2033 (sponsor estimate) | Locked | Locked | |
| Nov 16, 2026, 8:47 AM ET | Completion date | Nov 9, 2026 (actual) | Locked | Locked | |
| Nov 13, 2026, 9:47 AM ET | Completion date | May 1, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 13, 2026, 9:47 AM ET | Completion date | Jul 2, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 13, 2026, 9:47 AM ET | Completion date | Aug 7, 2026 (actual) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Jan 29, 2027 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Mar 21, 2033 (sponsor estimate) | Locked | Locked | |
| Nov 12, 2026, 8:11 AM ET | Completion date | Oct 28, 2026 (actual) | Locked | Locked |
- Detected Nov 19, 2026, 8:47 AM ETCompletion dateNCT04652076GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabMRK
- Now
- Nov 16, 2026 (actual)
- Before
- Locked
- Detected Nov 19, 2026, 8:47 AM ETCompletion date
- Now
- Jun 30, 2030 (sponsor estimate)
- Before
- Locked
- Detected Nov 17, 2026, 9:52 AM ETCompletion date
- Now
- Oct 27, 2026 (actual)
- Before
- Locked
- Detected Nov 17, 2026, 9:52 AM ETCompletion date
- Now
- Aug 19, 2031 (sponsor estimate)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT04652076GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabMRK
- Now
- Dec 31, 2026 (sponsor estimate)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT06502743First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without...MRK
- Now
- Dec 27, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT07015853ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and RadiationMRKINCY
- Now
- Dec 2033 (sponsor estimate)
- Before
- Locked
- Detected Nov 16, 2026, 8:47 AM ETCompletion dateNCT04713514OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCMRK
- Now
- Nov 9, 2026 (actual)
- Before
- Locked
- Detected Nov 13, 2026, 9:47 AM ETCompletion dateNCT05612035Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With...MRK
- Now
- May 1, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 13, 2026, 9:47 AM ETCompletion dateNCT07159763A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)MRK
- Now
- Jul 2, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 13, 2026, 9:47 AM ETCompletion dateNCT04895722Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite...MRK
- Now
- Aug 7, 2026 (actual)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT06688058A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)MRK
- Now
- Jan 29, 2027 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion dateNCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)MRKEXEL
- Now
- Mar 21, 2033 (sponsor estimate)
- Before
- Locked
- Detected Nov 12, 2026, 8:11 AM ETCompletion date
- Now
- Oct 28, 2026 (actual)
- Before
- Locked
The previous value and the sponsor's record update date are locked on 14 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerTracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.
What is on this list
Changes Signal8 recorded between two refreshes of a trial's ClinicalTrials.gov record: status, primary completion and completion dates, and results first posted. A change is shown when it was detected, which can be days after the sponsor updated the record. Nothing here describes what a trial showed.
New registrations, enrollment, eligibility and outcome-measure edits are not recorded. A status change is the registry's own word for where the trial stands, and "results posted" means results were posted to the registry, never what they show.
Free readers see the first 25 changes of any filter with the new value. The previous value, the sponsor's record update date and later pages are part of the plan. See the methodology.